[1]张国臣 常玉喜 韩 磊 徐 欣 赵 明 陈忠平.新诊断胶质瘤MGMT基因启动子甲基化水平定量分析[J].中国临床神经外科杂志,2020,(06):374-376.[doi:10.13798/j.issn.1009-153X.2020.06.012]
 ZHANG Guo-chen,CHANG Yu-xi,HAN Lei,et al.Quantitative analysis of methylation level of MGMT gene promoter in newly diagnosed glioma[J].,2020,(06):374-376.[doi:10.13798/j.issn.1009-153X.2020.06.012]
点击复制

新诊断胶质瘤MGMT基因启动子甲基化水平定量分析()
分享到:

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2020年06期
页码:
374-376
栏目:
论著
出版日期:
2020-06-15

文章信息/Info

Title:
Quantitative analysis of methylation level of MGMT gene promoter in newly diagnosed glioma
文章编号:
1009-153X(2020)06-0374-03
作者:
张国臣 常玉喜 韩 磊 徐 欣 赵 明 陈忠平
450008 郑州,郑州大学附属肿瘤医院神经外科(张国臣、韩 磊、徐 欣、赵 明),分子病理科(常玉喜);510060 广州,中山大学附属肿瘤医院神经外科/神经肿瘤科(陈忠平)
Author(s):
ZHANG Guo-chen1 CHANG Yu-xi2 HAN Lei1 XU Xin1 ZHAO Ming1 CHEN Zhong-ping3.
1. Department of Neurosurgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China; 2. Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China; 3. Department of Neurosurgery/Neuro-oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
关键词:
脑胶质瘤O6-甲基鸟嘌呤-DNA甲基转移酶甲基化定量分析
Keywords:
Glioma O6-methylguanine-DNA methyltransferase Methylation Quantitative analysis
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2020.06.012
文献标志码:
A
摘要:
目的 探讨新诊断胶质瘤O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)基因启动子甲基化(简称MGMT甲基化)水平的变化。方法 回顾性分析2016年1月至2019年6月郑州大学附属肿瘤医院神经外科收治的225例新诊断胶质瘤的临床资料,定量分析MGMT甲基化。结果 新诊断胶质瘤MGMT甲基化水平为(23.68±14.88)%,阳性率89.33%。≥40岁病人MGMT甲基化水平[(24.89±15.67)%]显著高于<40岁病人[(19.85±11.31)%;P<0.05]。少突胶质细胞瘤MGMT甲基化水平[(30.41±12.99)%]显著高于其他类型的胶质瘤[星形细胞瘤为(20.81±13.53)%、少突星形细胞瘤为(23.00±8.21)%、胶质母细胞瘤为(23.39±17.85)%;P<0.05]。胶质瘤MGMT甲基化水平与病人年龄呈正相关(r=0.135,P<0.05),而与病人性别和肿瘤级别无明显关系(P>0.05)。结论 新诊断胶质瘤MGMT甲基化水平与病人与年龄正相关,少突胶质细胞瘤MGMT甲基化水平明显高于其他类型胶质瘤
Abstract:
Objective To explore the change of methylation level of O6-methylguanine-DNA methyltransferase (MGMT) gene promoter in newly diagnosed glioma. Methods The methylation level of MGMT gene promoter of 225 newly diagnosed glioma patients who were admitted to our hospital from January 2016 to June 2019 were analyzed retrospectively. Results The mean methylation level of MGMT gene promoter in newly diagnosed glioma patients was (23.68+14.88)% with a positive rate of 89.33%. The methylation level in patients over 40 years [(24.89+15.67)%] was significantly higher than that [(19.85 +11.31)%] under 40 years (P<0.05). The methylation level was significantly higher in patients with oligodendroglioma [(30.41+12.99)%] than patients with astrocytoma [(20.81+13.53)%, P<0.05], oligoastrocytoma [(23.00±8.21)%, P<0.05], or glioblastoma [(23.39±17.85)%, P<0.05]. There were no significant differences in the methylation level between different gender and grade of tumour (P>0.05). The methylation level of MGMT was positively related to the age (r=0.135, P<0.05), but not related to the gender and the grade of glioma (P>0.05). Conclusions The methylation level of MGMT gene promoter is not related to the gender and the grade of glioma, but positively related to the age. The methylation level of MGMT of oligodendroglioma is higher than other glioma types

参考文献/References:

[1] 赵庭生. MGMT基因甲基化在胶质瘤化疗中的意义[J]. 中国临床神经外科杂志,2010,15(6):378-380.
[2] Colella S, Shen L, Baggerly KA, et al. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites [J]. Biotechniques, 2003, 35(1): 146-150.
[3] Ovchinnikov DA, Cooper MA, Pandit P, et al. Tumor-suppressor gene promoter hypermethylation in saliva of head and neck cancer patients [J]. Transl Oncol, 2012, 5(5): 321-326.
[4] 赵宇航,王泽芬,徐成仕,等. 人脑胶质瘤IDH1突变状态与MGMT启动子甲基化、P53和TERT突变相关性[J]. 中国临床神经外科杂志,2018,23(5):339-342.
[5] 徐立新,张新定. MGMT与胶质瘤相关研究进展[J]. 中华神经医学志,2011,10(6):574-577.
[6] 许洪升,张俊英,岳伟英,等. 脑胶质瘤MGMT表达与体外药敏相关性及其临床意义[J]. 中国临床神经外科杂志,2007,12(5):263-266.
[7] Araki Y, Mizoguchi M, Yoshimoto K, et al. Quantitative digital assessment of MGMT immunohistochemical expre-ssion in glioblastoma tissue [J]. Brain Tumor Pathol, 2011, 28(1): 25-31.
[8] 郝振强,卢培刚,袁绍纪,等. MGMT表达检测指导恶性脑胶质瘤个体化化疗研究[J]. 中华神经外科疾病研究杂志,2013,12(3):262-264.
[9] Pulling LC, Divine KK, Klinge DM, et al. Promoter hyper-methylation of the O6-methylguanine-DNA methyltrans-ferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression [J]. Cancer Res, 2003, 63(16): 4842-4848.
[10] Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine [J]? Nat Rev Neurol, 2010, 6(8): 39-51.
[11] 黄 磊,江 涛,袁 芳,等. MGMT基因甲基化在胶质瘤化疗及预后中的意义[J]. 中国微侵袭神经外科杂志,2007,12(10):474-477.
[12] 宫惠琳,梁 华,张娇娇,等. 少突胶质细胞瘤中染色体1p/19q联合缺失与MGMT基因启动子甲基化的相关性[J]. 肿瘤防治研究,2018,45(8):550-554.
[13] 唐天友,许莹莹,王建设,等. 人脑胶质瘤组织MGMT和EGFR及Ki-67表达临床意义分析[J]. 中华肿瘤防治杂志,2013,20(11):840-844.
[14] 陈 功,吴 惺,谢 嵘,等. 胶质母细胞瘤MGMT基因启动子甲基化、MGMT蛋白表达和预后相关性分析[J]. 中国临床神经科学,2017,25(2):135-142.

相似文献/References:

[1]付 锴 江普查 宫 睿 王 伟.表达VASH1基因的人脑胶质瘤U-87MG细胞对化疗药物敏感性的变化[J].中国临床神经外科杂志,2016,(01):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
 FU Kai,JIANG Pu-cha,GONG Rui,et al.Effect of lentiviral vector-mediated VASH1 gene on chemosensitivity of human glioma U-87MG cells[J].,2016,(06):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
[2]崔焕喜,柳 琛.多模态MRI、神经导航和超声在脑胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(11):721.[doi:10.13798/j.issn.1009-153X.2016.11.027]
[3]常丙林.恶性脑胶质瘤组织MGMT的表达及临床意义[J].中国临床神经外科杂志,2017,(03):171.[doi:10.13798/j.issn.1009-153X.2017.03.015]
 CHANG Bing-lin..Expression of MGMT in malignant glioma tissues and its clinical meaning[J].,2017,(06):171.[doi:10.13798/j.issn.1009-153X.2017.03.015]
[4]闫 珊 徐善才.多学科护理照顾模式对脑胶质瘤术后病人自我护理能力的影响[J].中国临床神经外科杂志,2017,(05):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
 YAN Shan,XU Shan-cai..Effects of multi-subjects nursing care model on self-care ability in patients with brain glioma after operation[J].,2017,(06):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
[5]罗似亮 夏之柏.脑胶质瘤病人脑脊液Midkine表达的临床意义[J].中国临床神经外科杂志,2017,(06):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
 LUO Si-liang,XIA Zhi-bo..Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas[J].,2017,(06):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
[6]呼铁民 褚会松 田 甜 王昆鹏 杨国军 杨立军 王维兴.脑胶质瘤ADAM17与EGFR的表达及临床意义[J].中国临床神经外科杂志,2017,(08):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
 HU Tie-min,CHU Hui-song,TIAN Tian,et al.Expressions of ADAM17 and EGFR in gliomas tissues and their clinical meanings[J].,2017,(06):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
[7]汪超甲 综述 王 辉 审校.脑胶质瘤化疗现状及耐药机制的研究进展[J].中国临床神经外科杂志,2017,(11):791.[doi:10.13798/j.issn.1009-153X.2017.11.023]
[8]高剑峰 姚庆和 李晓辉 龙宇波 陈振波.脑胶质瘤miR-9、PPARγ表达水平及临床意义[J].中国临床神经外科杂志,2018,(01):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
 GAO Jian-feng,YAO Qing-he,LI Xiao-hui,et al.Expressions of miR-9 and PPARγ in human brain gliomas and their clinical meanings[J].,2018,(06):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
[9]刘 靖 吴立权 黄书岚.聚焦解决模式对脑胶质瘤术后病人自我管理效能感及生命意义的影响[J].中国临床神经外科杂志,2018,(03):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
 LIU Jing,WU Li-quan,HUANG Shu-lan..Effects of solution focused intervention on self-management efficacy and meanings of life in the patients with gliomas after surgery[J].,2018,(06):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
[10]赵宇航 王泽芬 徐成仕 李 凯 李志强.人脑胶质瘤IDH1突变状态与MGMT启动子甲基化、P53和TERT突变相关性[J].中国临床神经外科杂志,2018,(05):339.[doi:10.13798/j.issn.1009-153X.2018.05.011]
 ZHAO Yu-hang,WANG Ze-fen,XU Cheng-shi,et al.Correlativity of IDH1 mutation with MGMT promoter methylation and P53 and TERT mutations in gliomas[J].,2018,(06):339.[doi:10.13798/j.issn.1009-153X.2018.05.011]

备注/Memo

备注/Memo:
(2019-12-10收稿,2020-01-21修回)通讯作者:赵 明,E-mail:zm6392@163.com
更新日期/Last Update: 2020-06-15